RTP Mobile Logo
Select Publications

John P Leonard, MD

Bannerji R et al. Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial. ASCO 2021;Abstract 7534.

Budde LE et al. Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: Pivotal results from a phase I/II study. ASH 2021;Abstract 127.

Budde LE et al. Mosunetuzumab plus polatuzumab vedotin has promising efficacy and a favorable safety profile in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: Updated results from a phase Ib/II study. ASH 2021;Abstract 533.

Hutchings M et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, Phase I/II study. Lancet 2021:398(10306):1157-69. Abstract

Hutchings M et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A Phase I trial. J Clin Oncol 2021;39(18):1959-70. Abstract

Lynch R et al. Efficacy and safety of parsaclisib in patients with relapsed or refractory follicular lymphoma: Primary analysis from a Phase 2 study (CITADEL-203). ASH 2021;Abstract 813.

Morschhauser F et al. Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R/R) follicular lymphoma (FL). ASH 2021;Abstract 128.

Morschhauser F et al. Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed/refractory follicular lymphoma: Initial results from a Phase Ib study. ASH 2021;Abstract 129.

Morschhauser F et al. Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: Final analysis of a Phase Ib/II trial. Blood Cancer J 2021;11(8):147. Abstract

Portell CA et al. Phase II study of venetoclax in combination with obinutuzumab and bendamustine in patients with high tumor burden follicular lymphoma as front line therapy (PrECOG 0403). ASH 2021;Abstract 814.

Schuster S et al. Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the Phase II ELARA trial. ASCO 2021;Abstract 7508.

Laurie H Sehn, MD, MPH

Batlevi CL et al. Characteristics of patients achieving complete or partial response (cr/pr) with tazemetostat (taz) in wild-type relapsed/refractory (r/r) follicular lymphoma (FL). 16th ICML 2021;Abstract 109.

Canales Albendea MA et al. Obinutuzumab short-duration infusion (SDI) in previously untreated advanced follicular lymphoma: Results from the end of induction analysis of the phase IV GAZELLE study. ASCO 2021;Abstract 7545.

Casulo C et al. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Adv 2021;5(6):1737-45. Abstract

Fowler NH et al. Umbralisib, a dual PI3K-delta/CK1-epsilon inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol 2021;39(15):1609-18. Abstract

Jacobson CA et al. Outcomes in ZUMA-5 with axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma who had the high-risk feature of early progression after first chemoimmunotherapy. EHA 2021;Abstract S213.

Kahl BS et al. Long term follow up of the Resort study (E4402): A randomized Phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. ASH 2021;Abstract 815.

Lansigan F et al. Completed induction phase analysis of Magnify: Phase 3b study of lenalidomide + rituximab (R2) followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma. ASH 2021;Abstract 812.

Matasar MJ et al. Copanlisib plus rituximab versus rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): A double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(5):678-89. Abstract

Morschhauser F et al. Six-year results from the Phase 3 randomized study Relevance show similar outcomes for previously untreated follicular lymphoma patients receiving lenalidomide plus rituximab (R2) versus rituximab-chemotherapy followed by rituximab maintenance. ASH 2021;Abstract 2417.

Neelapu SS et al. Long-term follow-up analysis of ZUMA-5: A Phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). ASH 2021;Abstract 93.

Trask P et al. Obinutuzumab short duration infusion is preferred by healthcare providers and has minimal impact on patient-reported symptoms among patients with untreated, advanced follicular lymphoma. ASH 2021;Abstract 1345.